1-20 of 35
chronic lymphocytic leukemia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL

Burcu Aslan, Gorkem Kismali, Lisa S. Chen, LaKesla R. Iles, Mikhila Mahendra, Michael Peoples, Mihai Gagea, Natalie W. Fowlkes, Xiaofeng Zheng, Jing Wang, Christopher P. Vellano, Joseph R. Marszalek, Maria Teresa Sabrina Bertilaccio, Varsha Gandhi
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3134–3146.
https://doi.org/10.1182/bloodadvances.2020003821
Published: 2021
Includes: Supplemental data
Journal Articles

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation

Clinical Trials & Observations
Oscar B. Lahoud, Sean M. Devlin, Molly A. Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce, Boglarka Gyurkocza, Guenther Koehne, James W. Young, Hugo R. Castro-Malaspina, Juliet N. Barker, Esperanza B. Papadopoulos, Ann A. Jakubowski, Andrew D. Zelenetz, Anthony R. Mato, Sergio A. Giralt, Miguel A. Perales, Craig S. Sauter
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2879–2889.
https://doi.org/10.1182/bloodadvances.2020003726
Published: 2021
Journal Articles

RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia

Stavroula Ntoufa, Marina Gerousi, Stamatia Laidou, Fotis Psomopoulos, Georgios Tsiolas, Theodoros Moysiadis, Nikos Papakonstantinou, Larry Mansouri, Achilles Anagnostopoulos, Niki Stavrogianni, Sarka Pospisilova, Karla Plevova, Antonios M. Makris, Richard Rosenquist, Kostas Stamatopoulos
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2788–2792.
https://doi.org/10.1182/bloodadvances.2020001717
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

Haesook T. Kim, Conner J. Shaughnessy, Sharmila C. Rai, Carol Reynolds, Vincent T. Ho, Corey Cutler, John Koreth, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Philippe Armand, Edwin P. Alyea, Joseph H. Antin, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4113–4123.
https://doi.org/10.1182/bloodadvances.2020002184
Published: 2020
Includes: Supplemental data
Journal Articles

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Lindsey E. Roeker, Peter Dreger, Jennifer R. Brown, Oscar B. Lahoud, Toby A. Eyre, Danielle M. Brander, Alan Skarbnik, Catherine C. Coombs, Haesook T. Kim, Matthew Davids, Steven T. Manchini, Gemlyn George, Nirav Shah, Timothy J. Voorhees, Kim H. Orchard, Harriet S. Walter, Arvind K. Arumainathan, Andrea Sitlinger, Jae H. Park, Mark B. Geyer, Andrew D. Zelenetz, Craig S. Sauter, Sergio A. Giralt, Miguel-Angel Perales, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3977–3989.
https://doi.org/10.1182/bloodadvances.2020001956
Published: 2020
Journal Articles

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8 + T-cell responses

Alak Manna, Timothy Kellett, Sonikpreet Aulakh, Laura J. Lewis-Tuffin, Navnita Dutta, Keith Knutson, Eduardo Chini, Javier Pinilla-Ibarz, Nicole Lamanna, Rami Manochakian, Fabio Malavasi, Taimur Sher, Asher A. Chanan-Khan, Sikander Ailawadhi, Aneel Paulus
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2143–2157.
https://doi.org/10.1182/bloodadvances.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Clinical Trials & Observations
Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1458–1463.
https://doi.org/10.1182/bloodadvances.2020001678
Published: 2020
Journal Articles

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Clinical Trials & Observations
Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, Sarah M. Gressett Ussery, Mecide Gharibo, Pavel Kiselev, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1407–1418.
https://doi.org/10.1182/bloodadvances.2019001145
Published: 2020
Includes: Supplemental data
Journal Articles

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez, Catherine J. Wu
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3759–3769.
https://doi.org/10.1182/bloodadvances.2019000367
Published: 2019
Journal Articles

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy

Mazyar Shadman, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Filippo Milano, Ang Li, Alexandre V. Hirayama, Mohamed L. Sorror, Sindhu Cherian, Xueyan Chen, Ryan D. Cassaday, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, David G. Maloney, Cameron J. Turtle
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3062–3069.
https://doi.org/10.1182/bloodadvances.2019000593
Published: 2019
Journal Articles

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials

Clinical Trials & Observations
Tomasz K. Wojdacz, Harindra E. Amarasinghe, Latha Kadalayil, Alice Beattie, Jade Forster, Stuart J. Blakemore, Helen Parker, Dean Bryant, Marta Larrayoz, Ruth Clifford, Pauline Robbe, Zadie A. Davis, Monica Else, Dena R. Howard, Basile Stamatopoulos, Andrew J. Steele, Richard Rosenquist, Andrew Collins, Andrew R. Pettitt, Peter Hillmen, Christoph Plass, Anna Schuh, Daniel Catovsky, David G. Oscier, Matthew J. J. Rose-Zerilli, Christopher C. Oakes, Jonathan C. Strefford
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2474–2481.
https://doi.org/10.1182/bloodadvances.2019000237
Published: 2019
Includes: Supplemental data
Journal Articles

IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia

Clinical Trials & Observations
Ganchimeg Ishdorj, Erin Streu, Pascal Lambert, Harbhajan S. Dhaliwal, Salaheddin M. Mahmud, Spencer B. Gibson, Versha Banerji, Aaron J. Marshall, James B. Johnston
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2188–2198.
https://doi.org/10.1182/bloodadvances.2018026591
Published: 2019
Includes: Supplemental data
Journal Articles

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

Elisavet Chartomatsidou, Stavroula Ntoufa, Konstantia Kotta, Alessandra Rovida, Maria Anna Akritidou, Daniela Belloni, Elisabetta Ferrero, Theoni Trangas, Niki Stavroyianni, Achilles Anagnostopoulos, Richard Rosenquist, Paolo Ghia, Nikos Papakonstantinou, Kostas Stamatopoulos
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1891–1896.
https://doi.org/10.1182/bloodadvances.2018030262
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019
Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Clinical Trials & Observations
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1553–1562.
https://doi.org/10.1182/bloodadvances.2018030007
Published: 2019
Journal Articles

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

Clinical Trials & Observations
Paolo Strati, Koichi Takahashi, Christine B. Peterson, Michael J. Keating, Philip A. Thompson, Naval G. Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan M. O'Brien, Hagop M. Kantarjian, William G. Wierda, P. Andrew Futreal, Alessandra Ferrajoli
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1533–1539.
https://doi.org/10.1182/bloodadvances.2019031336
Published: 2019
Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1167–1174.
https://doi.org/10.1182/bloodadvances.2018030221
Published: 2019
Includes: Supplemental data
Journal Articles

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova
Journal: Blood Advances
Blood Adv (2019) 3 (6): 897–907.
https://doi.org/10.1182/bloodadvances.2018029371
Published: 2019
Includes: Supplemental data